Abstract
ABSTRACT
Successful use of doxorubicin as an antitumor agent is limited by its cardiotoxicity, which takes different forms and results from multiple biochemical alterations in the cell. This study addresses the possibility to overcome these adverse effects by studying the effects of N-(2-hydroxypropyl)methacrylamide (HPMA) polymer, which contains doxorubicin attaching to it. Both time-and dose-dependent studies were conducted using DU145 cell lines. The results of this study reveal that doxorubicin attached to HPMA can be used successfully in treating cancer instead of doxorubicin alone, which may open a new gate for clinicians and scientists, leading to overcoming the resistance and side effects of the currently used antitumor agents.